Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension

Abstract

ObjectiveTo assess the long-term efficacy and safety of infliximab plus methotrexate in juvenile rheumatoid arthritis (JRA).MethodsPatients eligible for the open-label extension (OLE, weeks 52–204) received infliximab 3–6 mg/kg every 8...